Category Archives: Lung cancer

X-396 update and info on liquid biopsy

Abstract 9056 is an update of info previously published on this site. The study involved 60 patients of whom 30 were ALK+ NSCLC. Of that 30, 19 (60%) had partial responses (PR). 8 patients were Crizotinib naive and of them … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects, X-396 - ensartinib from Xcovrery | Leave a comment

Alectinib Japan trial abstract

Abstract 9008 covers the J-ALEX phase 3 trial comparing Crizotinib (arm A) with Alectinib (arm B) in TKI naive patients. There were 207 patients at 41 centers in Japan randomized between the two arms. Arm A had a median PFS … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment | Leave a comment

Lorlatinib abstract

Abstract 9009 is a phase 1 dose escalation trial (dose levels ranged from 10-200 mg and the Recomended phas 2 dose was 100 mg once daily). There were 54 patients as of November 30, 2015. 41 are ALK positive and … Continue reading

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Britatinib abstract

Abstract 9007 covers the Phase 2 trial (ALTA) comparing two dosing schemes. There were 222 patients who had progressed on Crizotinib. Results where as of 12-7-15. Arm A received 90 mg straight through. ¬†Arm Breceived 90 mg for the first … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Some Summaries of ASCO abstracts

So there are actually 128 different abstracts that use the term ALK in either the body or the title of the abstract. I can not look at all of them. If you want to look them over you can go … Continue reading

Posted in Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Upcoming ASCO abstracts

There are 14 abstracts for the upcoming ASCO that have ALK in the title. But only 6 look like they are likely to be broadly applicable to people on this board. I will be posting summaries over the next week … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer | Leave a comment

Entrectinib phase 1-2 trial update

Entrectinib was tested in 119 patients with three kinds of mutations: NTRK+, ALK, and ROS1. Efficacy data was reported for 24 patients. For ALK there appear to have been 5 patients, and 57% of them had a tumor response (presumably … Continue reading

Posted in Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects | Leave a comment

Ensartinib (X396) trial update

63 patients in trial but only 35 are ALK+, NSCLC, and treated at 200 to 250 mg daily. Of those, 8 were ALK inhibitor naive, 7 (88%) had an objective response. 19 patients had received Crizotinib but not another ALK … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects, X-396 - ensartinib from Xcovrery | Leave a comment

Additional Brigatinib info

Ariad has posted a new presentation from European Lung Cancer Conference on their website for a limited time. Pages 7-13 are most relevant. Page 8 shows a breakdown of how patients ¬†responded by dose. 90 mg had a ORR of … Continue reading

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Ariad announces start of Phase 3 trial

Ariad today announced the initiation of a first line phase 3 trial comparing Brigatinib with Crizotinib. Patients must be ALK inhibitor naive. They are planning to enroll around 270 patients. They expect to complete enrollment in 2018. Of interest, the … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, Research | Leave a comment